Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Adenocarcinoma in Situ / epidemiology Adolescent Adult Age Factors DNA, Viral / isolation & purification Female Human papillomavirus 16 / genetics Human papillomavirus 18 / genetics Humans Incidence Mass Screening / statistics & numerical data Papillomavirus Infections / epidemiology Papillomavirus Vaccines / therapeutic use Precancerous Conditions / epidemiology Uterine Cervical Neoplasms / diagnosis Young Adult Uterine Cervical Dysplasia / epidemiology
AIS HPV adenocarcinoma in situ cervical cancer cervical intraepithelial lesions

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 02 2020
Historique:
received: 18 01 2019
revised: 19 03 2019
accepted: 01 04 2019
pubmed: 14 4 2019
medline: 12 2 2020
entrez: 14 4 2019
Statut: ppublish

Résumé

Primary prevention through the use of human papillomavirus (HPV) vaccination is expected to impact both cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS). While CIN is well described, less is known about the epidemiology of AIS, a rare cervical precancer. We identified AIS and CIN grade 3 (CIN3) cases through population-based surveillance, and analyzed data on HPV types and incidence trends overall, and among women screened for cervical cancer. From 2008 to 2015, 470 AIS and 6,587 CIN3 cases were identified. The median age of women with AIS was older than those with CIN3 (35 vs. 31 years; p < 0.01). HPV16 was the most frequently detected type in both AIS and CIN3 (57% in AIS; 58% in CIN3), whereas HPV18 was the second most common type in AIS and less common in CIN3 (38% vs. 5%; p < 0.01). AIS lesions were more likely than CIN3 lesions to be positive for high-risk types targeted by the bivalent and quadrivalent vaccines (HPV16/18, 92% vs. 63%; p < 0.01), and 9-valent vaccine (HPV16/18/31/33/45/52/58, 95% vs. 87%; p < 0.01). AIS incidence rates decreased significantly in the 21-24 year age group (annual percent change [APC] overall: -22.1%, 95% CI: -33.9 to -8.2; APC among screened: -16.1%, 95% CI: -28.8 to -1.2), but did not decrease significantly in any older age group. This report on the largest number of genotyped AIS cases to date suggests an important opportunity for vaccine prevention of AIS, and is the first to document a decline in AIS incidence rates among young women during the vaccine era.

Identifiants

DOI: 10.1002/ijc.32340 PMID: 30980692 PMC: PMC9112013
pubmed: 30980692
doi: 10.1002/ijc.32340
pmc: PMC9112013
mid: NIHMS1806590
doi:

Substances chimiques

DNA, Viral 0
Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

810-818

Subventions

Organisme : CDC HHS
ID : U50CK000486 [New York]
Pays : United States
Organisme : CDC HHS
ID : U50CK000484 [Oregon]
Pays : United States
Organisme : ACL HHS
ID : U54CK000482
Pays : United States
Organisme : CDC HHS
ID : U50CK000491 [Tennessee]
Pays : United States
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000482
Pays : United States
Organisme : CDC HHS
ID : U50CK000488 [Connecticut]
Pays : United States
Organisme : ACL HHS
ID : U54CK000484
Pays : United States
Organisme : CDC HHS
ID : U50CK000482 [California]
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000484
Pays : United States

Informations de copyright

© 2019 UICC.

Références

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
Cancer Causes Control. 2015 May;26(5):741-7
pubmed: 25724415
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):645-50
pubmed: 19827887
Cancer Med. 2017 Feb;6(2):416-423
pubmed: 28102052
Cancer. 2004 Mar 1;100(5):1035-44
pubmed: 14983500
Cancer. 2004 Oct 25;102(5):280-7
pubmed: 15376198
Clin Infect Dis. 2019 Apr 8;68(8):1282-1291
pubmed: 30137283
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):602-609
pubmed: 30792242
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):230-40
pubmed: 25363635
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
Gynecol Oncol. 2000 Aug;78(2):97-105
pubmed: 10926787
J Natl Cancer Inst. 2008 May 7;100(9):622-9
pubmed: 18445828
Prev Med. 2017 Oct;103:60-65
pubmed: 28765084
Lancet Oncol. 2011 Jul;12(7):663-72
pubmed: 21684207
Int J Cancer. 2008 Apr 1;122(7):1684-5
pubmed: 18059025
Cancer. 2016 Dec 1;122(23):3682-3686
pubmed: 27657992
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Prev Med. 2017 Jul;100:243-247
pubmed: 28502575
Int J Cancer. 2015 Dec 15;137(12):2858-68
pubmed: 26096203
J Natl Cancer Inst. 2006 Mar 1;98(5):303-15
pubmed: 16507827
Vaccine. 2015 Mar 24;33(13):1608-13
pubmed: 25681664
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Am J Public Health. 2016 Dec;106(12):2211-2218
pubmed: 27736208
Papillomavirus Res. 2016 Dec;2:61-69
pubmed: 29074187
Br J Cancer. 2003 Sep 1;89(5):886-90
pubmed: 12942122
Int J Cancer. 2011 Feb 15;128(4):927-35
pubmed: 20473886
Vaccine. 2008 Aug 19;26 Suppl 10:K1-16
pubmed: 18847553
Gynecol Oncol. 2009 Sep;114(3):390-4
pubmed: 19500822
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305
JAMA Oncol. 2017 Jun 01;3(6):833-837
pubmed: 27685805
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598
Cancer Causes Control. 2014 May;25(5):571-81
pubmed: 24578200
Br J Cancer. 2006 Jan 16;94(1):171-5
pubmed: 16404371
Obstet Gynecol. 2003 Jan;101(1):38-45
pubmed: 12517643
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312
pubmed: 22711081
Obstet Gynecol. 1988 Jun;71(6 Pt 1):842-4
pubmed: 3285263
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
Int J Cancer. 2011 Mar 15;128(6):1344-53
pubmed: 20949623
Int J Cancer. 2010 Oct 15;127(8):1923-30
pubmed: 20473898
Arch Pathol Lab Med. 2014 Apr;138(4):453-83
pubmed: 24678677
Cancer. 2008 Nov 15;113(10 Suppl):2855-64
pubmed: 18980204
Int J Cancer. 2014 Jul 1;135(1):88-95
pubmed: 24382655
Am J Prev Med. 2018 Aug;55(2):197-204
pubmed: 29859731
J Womens Health (Larchmt). 2012 Oct;21(10):1031-7
pubmed: 22816437
Arch Pathol Lab Med. 2015 Nov;139(11):1431-6
pubmed: 25951104
Cancer. 2005 Mar 15;103(6):1258-64
pubmed: 15693030
Am J Obstet Gynecol. 2017 Mar;216(3):272.e1-272.e7
pubmed: 27908632
Am J Clin Pathol. 2012 Apr;137(4):516-42
pubmed: 22431528
J Infect Dis. 2012 Dec 15;206(12):1878-86
pubmed: 23045628

Auteurs

Angela A Cleveland (AA)

Centers for Disease Control and Prevention, Atlanta, GA, USA.
ORCID: 0000-0003-1375-8964

Julia W Gargano (JW)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Ina U Park (IU)

Department of Family and Community Medicine, School of Medicine, University of California San Francisco, San Francisco, CA, USA.

Marie R Griffin (MR)

Vanderbilt University Medical Center, Nashville, TN, USA.

Linda M Niccolai (LM)

Yale School of Public Health, New Haven, CT, USA.

Melissa Powell (M)

Oregon Department of Human Services, Portland, OR, USA.

Nancy M Bennett (NM)

University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Kayla Saadeh (K)

California Emerging Infections Program, Oakland, CA, USA.

Manideepthi Pemmaraju (M)

Vanderbilt University Medical Center, Nashville, TN, USA.

Kyle Higgins (K)

Yale School of Public Health, New Haven, CT, USA.

Sara Ehlers (S)

Oregon Department of Human Services, Portland, OR, USA.

Mary Scahill (M)

University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Michelle L Johnson Jones (ML)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Troy Querec (T)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lauri E Markowitz (LE)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Elizabeth R Unger (ER)

Centers for Disease Control and Prevention, Atlanta, GA, USA.
ORCID: 0000-0002-2925-5635

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › États, signes et symptômes pathologiques › Résultats morphologiques et microscopiques › Adénocarcinome in situ › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Personnes › Tranches d'âge › Adolescent › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs âges › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › ADN viral › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Virus › Virus oncogènes › Virus tumoraux à ADN › Papillomaviridae › Virus des Papillomavirus humains › Papillomavirus humain de type 16 › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Virus › Virus oncogènes › Virus tumoraux à ADN › Papillomaviridae › Virus des Papillomavirus humains › Papillomavirus humain de type 18 › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Pratiques en santé publique › Dépistage de masse › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies sexuellement transmissibles › Maladies sexuellement transmissibles virales › Infections à papillomavirus › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre les papillomavirus › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Tumeurs › États précancéreux › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital féminin › Tumeurs de l'utérus › Tumeurs du col de l'utérus › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Jeune adulte › Cervical adenocarcinoma in situ: Human...
Recherchemedicale.com › Maladies urogénitales › Maladies génitales › Maladies de l'appareil génital féminin › Maladies de l'utérus › Maladies du col utérin › Dysplasie du col utérin › Cervical adenocarcinoma in situ: Human...